Here are 3 top Betashares ETFs I'd buy now

Betashares offers plenty of ways to invest beyond the Australian share market.

For investors looking for long-term growth, these three exchange-traded funds (ETFs) stand out to me.

Betashares Global Healthcare Currency Hedged ETF (ASX: DRUG)

The DRUG ETF gives investors access to some of the world's largest healthcare companies in a single ASX investment.

Its holdings include Johnson & Johnson, Eli Lilly, and AstraZeneca. This gives the fund exposure to businesses developing medicines, medical technology, diagnostics, and other products used across global healthcare systems.

I like healthcare as a long-term investment because demand should be supported by some powerful trends. Populations are ageing in many countries, living standards are rising, and medical innovation continues to create new treatments for diseases that were once difficult to manage.

The DRUG ETF is also hedged into Australian dollars. This reduces the impact of movements in foreign currencies on returns, allowing the performance of the underlying healthcare companies to have a greater influence on the investment outcome.

Betashares Global Quality Leaders ETF (ASX: QLTY)

The QLTY ETF takes a quality-focused approach to global investing.

Instead of simply buying the world's largest companies, the fund tracks an index containing 150 businesses ranked using measures including return on equity, debt levels, cash flow generation, and earnings stability.

I like that approach because these are characteristics I would naturally look for when choosing individual shares.

Strong cash generation can give a company more freedom to invest in new products or markets. Lower debt can provide greater flexibility when economic conditions become difficult, while consistent earnings can be a sign of a durable business.

The current portfolio includes companies such as Arista Networks, Palantir Technologies, Microsoft, and Visa.

That gives this Betashares ETF exposure to a range of industries across global markets.

Betashares Electric Vehicles and Future Mobility ETF (ASX: DRIV)

The DRIV ETF is the most specialised of my three picks.

Electric vehicles are the obvious part of the story, but I think the opportunity is larger than simply predicting which car manufacturer will sell the most vehicles.

Modern cars are becoming increasingly reliant on semiconductors, sensors, software, batteries, autonomous driving technology, and other advanced components. Betashares designed the fund to invest in up to 50 global companies involved in this changing automotive industry.

Its exposure includes businesses such as Tesla, NIO, Aptiv, and Volvo.

I think the move towards smarter and increasingly electrified vehicles could continue for many years, creating opportunities across several parts of the automotive supply chain.

However, as a thematic investment, this Betashares ETF could experience greater volatility than a broad global fund. But for investors comfortable with that risk, I think it offers a way to invest in how transport technology could change over the coming decade.

Foolish takeaway

These three Betashares ETFs each give investors access to long-term opportunities.

The DRUG ETF provides exposure to global healthcare, the QLTY ETF focuses on financially strong global businesses, and the DRIV ETF targets the changing automotive industry.

I think any one, or all three, could be worth considering for investors looking to build wealth over many years.

The post Here are 3 top Betashares ETFs I'd buy now appeared first on The Motley Fool Australia.

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Arista Networks, AstraZeneca Plc, Eli Lilly, Microsoft, Palantir Technologies, Tesla, and Visa. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Johnson & Johnson. The Motley Fool Australia has recommended Arista Networks, Microsoft, and Visa. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026